BioSpace Insights
The BioSpace Insights team performs research and analysis on industry trends for BioSpace and clients, producing industry reports, podcasts, events and articles.
Shaping the Future of Drug Development
LIVE WEBINAR | APRIL 23 | 1PM–2PM EST
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. We will also discuss the ripple effect these changes are having on a global scale. Our guests will provide their insights from investor, regulatory and legal perspectives to unpack the latest changes to guidance and communications their impacts on market and development strategies, cross-border collaboration, and legal frameworks.
LIVE WEBINAR | APRIL 23 | 1PM–2PM EST
In this discussion, our guests explore how recent regulatory changes are shaping the future of AI in drug development in the US market. We will also discuss the ripple effect these changes are having on a global scale. Our guests will provide their insights from investor, regulatory and legal perspectives to unpack the latest changes to guidance and communications their impacts on market and development strategies, cross-border collaboration, and legal frameworks.
Listen to Denatured
Unravel the business of science with BioSpace.
In this episode of Denatured, Lori and guests from Teva Pharmaceuticals and TOWER Capital review the investment landscape this year and the policies influencing investment heading into 2025.
In the third episode of our mini series on artificial intelligence, Lori and guests continue their exploratory discussion on AI and the opportunity in patient lives.
In this episode, Lori and guests continue their exploratory discussion on AI and focus on the challenges of globalization and return on investment.
Webinars
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
BioSpace at 2025 SCOPE Summit
Events
In this live panel discussion, speakers focused on the EU AI Act’s global regulatory implications for medical devices & QARA’s future. An executive summary is available.
- BIO International Convention: June 16-19, 2025 | Boston, MA
- Bioprocessing Summit: August 18-21, 2025 | Boston, MA
- Meeting on the Mesa: October 6-8, 2025 | Phoenix, AZ
BioSpace x DIA
The groundwork being done in 2024 is building the foundation for global collaboration in the future.
DRUG DEVELOPMENT
DRUG DEVELOPMENT
FROM BIOSPACE INSIGHTS
Federal funding and legislation spotlight women’s health opportunities and challenges.
The pharmaceutical industry is facing critical attention, particularly around drug pricing and development costs. Drug development cost is about 10% of the total healthcare spend in the United States. Broader issues such as local monopolies, utilization, unit, and costs and local monopolies, politics and a fragmented payer system contribute to the increasingly high costs to patients.
This week, we’re talking money! Following the release of BioSpace’s 2024 Salary Report, we discuss salary trends and how they are impacting the biopharma workforce.
GenAI, the youngest of the AI family, is evolving quickly. The global life sciences industry is attempting to evolve with it. However, as a keynote session at DIA’s MASC suggests, taking a pause to understand AI risks and to prepare to comply with the EU AI Act is what is needed.
BioSpace’s 2024 Salary Report explores the average salaries and salary trends of life sciences professionals.
This episode focuses on a healthy discussion regarding the IRA, particularly the unintended consequences to small molecule development within the industry and for patients.
These days you can hardly move without figuratively bumping into antibody-drug conjugates (ADCs). This week we discuss Pfizer’s strategic priorities for oncology - focused on ADCs and less on small molecules - and how the market is being influenced by the IRA.
This episode explores the drug pricing gap between consumer experience and industry norms. Join Lori and our KOLs as we explore the drivers of healthcare costs, the CBO, rebates, and overall spend in this new series.
With over 20% of people born between 1997 and 2003 identifying as a sexual and gender minority, moderated panels at SCOPE 2024 discuss the need to engage this community in clinical trials.
This week Lori, Greg and Tyler discuss the Accelerated Approval of Amtagvi, the first one-time cell therapy for solid tumors and the first TIL therapy; the FTC and HHS probe into generic drug shortages and some recent ADC-focused raises from ProfoundBio and Firefly Bio.